Research
Hormonal
Insulin resistance is the primary driver of diabetic dyslipidemia, causing elevated triglycerides, low HDL-C, and small dense LDL particles through increased hepatic VLDL secretion and altered lipoprotein metabolism.
If you have Type 2 Diabetes or Insulin Resistance, your high triglycerides and low HDL are likely driven by your body's resistance to insulin, not just what you eat. Focus on improving insulin sensitivity through weight loss, exercise, and medical management, as this addresses the root cause of the lipid abnormalities.
StrongSupportsVERY_HIGH confidence
Insulin resistance is the main underlying abnormality causing diabetic dyslipidemia. IR plays a central role in the abnormal lipid and lipoprotein metabolism of T2DM [1] as evidenced by the characteristic set of lipid and lipoprotein abnormalities accompanying IR, even in the absence of frank hyperglycemia or abnormal glucose tolerance.
Why this rating
Based on extensive epidemiologic studies, animal models, and clinical trials cited throughout the chapter.
Source
Lipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals
Gissette Reyes‐Soffer et al. · 2015
DOI 10.1002/9781118387658.ch17
book_chapter
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Statins are the first-line pharmacologic therapy for lowering LDL-C and reducing cardiovascular events in patients with Type 2 Diabetes, regardless of baseline cholesterol levels.Strong
- Lifestyle interventions (weight loss, diet, exercise) are key to treating diabetic dyslipidemia and can significantly reduce the incidence of Type 2 Diabetes in prediabetic individuals.Strong
- Targeting HDL-C and Triglycerides with non-statin drugs (niacin, fibrates) added to statins does not provide additional cardiovascular benefit compared to statin therapy alone in most cases.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →